AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE

Their core work

Azienda Sanitaria Universitaria Friuli Centrale is a university hospital and health authority based in Udine, Italy, that combines clinical care with clinical research. Their H2020 involvement centers on rare diseases, paediatric clinical trials, and data-driven medicine — acting as a clinical site and domain expert within large European research networks. They contribute real-world patient data, clinical expertise, and trial infrastructure to multi-country consortia tackling conditions where evidence gaps are greatest.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2017) covered diverse topics — nanostructured diagnostics, neonatal neuroprotection, and autoimmune disease cohort studies — suggesting an exploratory phase contributing clinical expertise across different calls. From 2018 onward, their focus sharpened decisively toward rare diseases and paediatric medicine, with three consecutive projects (c4c, EJP RD, ERICA) all building European-scale clinical research infrastructure for underserved patient populations. The shift from isolated clinical contributions to sustained engagement in rare disease networks signals a strategic commitment to this field.

They are consolidating as a clinical partner within Europe's rare disease and paediatric trial ecosystem, making them increasingly relevant for consortia in these areas.

How they like to work

They exclusively join projects as participants or third parties — never as coordinator — which positions them as a reliable clinical site bringing patient access and domain expertise rather than project management. Their 236 unique partners across 37 countries reflect involvement in very large consortia (c4c alone had 50+ partners), meaning they are experienced in navigating complex multi-site collaborations. This is a dependable clinical contributor, not a project driver.

With 236 unique consortium partners across 37 countries, they have an exceptionally broad European network built through participation in major health research infrastructures. Their connections span university hospitals, pharmaceutical companies, and rare disease patient organizations across nearly all EU member states.

What sets them apart

As a university hospital authority rather than a pure research institute, they bring something most academic partners cannot: direct access to patient populations within a functioning healthcare system. Their dual focus on rare diseases and paediatric medicine places them at the intersection of two areas where clinical trial sites are chronically scarce. For consortium builders, they offer an Italian clinical site with established experience in FAIR data sharing, regulatory compliance for paediatric trials, and integration into the EJP RD and IRDiRC ecosystems.

Highlights from their portfolio

• c4c
  Their largest funded project (EUR 476K) — conect4children is a flagship European network building permanent infrastructure for paediatric clinical trials.
• EJP RD
  The European Joint Programme on Rare Diseases is one of the most significant rare disease coordination efforts in H2020, covering FAIR data, omics, and translational research.
• ERICA
  A coordination and support action directly aligned with IRDiRC goals, indicating deep integration into the European rare disease policy and research landscape.